ReviewCalcified tissue international2018
Hallmarks of Bone Metastasis.
Review in Calcified tissue international, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 52 citations in OpenAlex.
- Association Between Immunohistochemical Profile and Radiographic Presentation of Breast Cancer Skeletal Metastases.Diagnostics (Basel, Switzerland) · 2026Article
- A Comparison of the Efficacy and Safety of Denosumab and Zoledronic Acid in Patients with Bone Metastatic Breast Cancer Receiving CDK4/6 Inhibitor Therapy.Medicina (Kaunas, Lithuania) · 2025Article
- Review on effects and mechanisms of plant-derived natural products against breast cancer bone metastasis.Heliyon · 2024Review
- Toll-like receptor-2 induced inflammation causes local bone formation and activates canonical Wnt signaling.Frontiers in immunology · 2024Article
- Amino Acid Metabolism in Bone Metastatic Disease.Current osteoporosis reports · 2023Review
- Multifunctional Zn and Ag co-doped bioactive glass nanoparticles for bone therapeutic and regeneration.Scientific reports · 2023Article
- GPR84 potently inhibits osteoclastogenesis and alleviates osteolysis in bone metastasis of colorectal cancer.Journal of orthopaedic surgery and research · 2023Article
- Expression pattern and clinical significance of β-catenin gene and protein in patients with primary malignant and benign bone tumors.Scientific reports · 2022Article
- Bone Marrow Niches and Tumour Cells: Lights and Shadows of a Mutual Relationship.Frontiers in immunology · 2022Review
- Prognostic factors and survival of patients undergoing surgical intervention for breast cancer bone metastases.Journal of bone oncology · 2021Article
- Efficacy of percutaneous vertebroplasty for the relief of osteoblastic spinal metastasis pain.Experimental and therapeutic medicine · 2021Article
- Astragalus polysaccharide attenuates LPS-related inflammatory osteolysis by suppressing osteoclastogenesis by reducing the MAPK signalling pathway.Journal of cellular and molecular medicine · 2021Article
- Bone marrow niches in the regulation of bone metastasis.British journal of cancer · 2021Review
- Local Bone Mineral Density, Subcutaneous and Visceral Adipose Tissue Measurements in Routine Multi Detector Computed Tomography-Which Parameter Predicts Incident Vertebral Fractures Best?Diagnostics (Basel, Switzerland) · 2021Article
- Bone Tropism in Cancer Metastases.Cold Spring Harbor perspectives in medicine · 2020Review
- Hypoxia in bone metastasis and osteolysis.Cancer letters · 2020Review
- The local and circulating SOX9 as a potential biomarker for the diagnosis of primary bone cancer.Journal of bone oncology · 2020Article
- Safety and Efficacy of Long-Term Zoledronic Acid in Advanced Breast Cancer with Bone Metastasis in South China.Journal of oncology · 2020Article
- Endoplasmic Reticulum Stress in Bone Metastases.Frontiers in oncology · 2020Review
- Molecular mechanisms and clinical management of cancer bone metastasis.Bone research · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
Breast cancer bone metastasis develops as the result of a series of complex interactions between tumor cells, bone marrow cells, and resident bone cells. The net effect of these interactions are the disruption of normal bone homeostasis, often with significantly increased osteoclast and osteoblast activity, which has provided a rational target for controlling tumor progression, with little or no emphasis on tumor eradication. Indeed, the clinical course of metastatic breast cancer is relatively long, with patients likely to experience sequential skeletal-related events (SREs), often over lengthy periods of time, even up to decades. These SREs include bone pain, fractures, and spinal cord compression, all of which may profoundly impair a patient's quality-of-life. Our understanding of the contributions of the host bone and bone marrow cells to the control of tumor progression has grown over the years, yet the focus of virtually all available treatments remains on the control of resident bone cells, primarily osteoclasts. In this perspective, our focus is to move away from the current emphasis on the control of bone cells and focus our attention on the hallmarks of bone metastatic tumor cells and how these differ from primary tumor cells and normal host cells. In our opinion, there remains a largely unmet medical need to develop and utilize therapies that impede metastatic tumor cells while sparing normal host bone and bone marrow cells. This perspective examines the impact of metastatic tumor cells on the bone microenvironment and proposes potential new directions for uncovering the important mechanisms driving metastatic progression in bone based on the hallmarks of bone metastasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.